Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 14/20 | 1.00 |
| ▸ | PRKAB1 | Q9Y478 | 14/20 | 1.00 |
| ▸ | PRKAA2 | P54646 | 12/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1443226 | 1.00 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL1445170 | 0.91 | PRKAG1 (0.84) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL12812675 | 0.90 | PRKAG1 (0.82) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL1445160 | 0.90 | PRKAG1 (0.82) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL1444448 | 0.90 | PRKAG1 (0.81) | PRKAG1PRKAB1PRKAA2PRKAA1MAPT | |
| SCHEMBL1444447 | 0.90 | PRKAG1 (0.81) | PRKAG1PRKAB1PRKAA2PRKAA1MAPT | |
| SCHEMBL1444701 | 0.88 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL1444064 | 0.88 | PRKAG1 (0.78) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL25692285 | 0.87 | PRKAG1 (0.88) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A | |
| SCHEMBL1444054 | 0.87 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288127-A1 | Novel Alkene Oxindole Derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8778973-B2 | Alkene oxindole derivatives | HOFFMANN-LAROCHE INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130131114-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| CN-102666485-A | Alkene oxindole derivatives and their uses to treat obesity, diabetes and hyperlipidemia | HOFFMANN LA ROCHE | 2012-09-12 | — | — | CN | disclosed |
| EP-2480530-A1 | ALKENE OXINDOLE DERIVATIVES AND THEIR USES TO TREAT OBESITY, DIABETES AND HYPERLIPIDEMIA | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011033099-A1 | ALKENE OXINDOLE DERIVATIVES AND THEIR USES TO TREAT OBESITY, DIABETES AND HYPERLIPIDEMIA | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
| US-20110071195-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-03-24 | — | — | US | disclosed |
| WO-2011032320-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288127-A1 | Novel Alkene Oxindole Derivatives | PRKAB1, PRKAR2A, PRKAB2 | PRKAG1 5/4885PRKAB1 1/4885PRKAA2 12/4885 |
| US-20110071195-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | PRKAB1, PRKAR2A, PRKAB2 | PRKAG1 5/4885PRKAB1 1/4885PRKAA2 13/4885 |
| US-20130131114-A1 | NOVEL ALKENE OXINDOLE DERIVATIVES | PRKAB1, PRKAR2A, PRKAB2 | PRKAG1 5/4885PRKAB1 1/4885PRKAA2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.